Advanced

TNF inhibition as therapy for rheumatoid arthritis.

Wollheim, Frank LU (2002) In Expert Opinion on Investigational Drugs 11(7). p.947-953
Abstract
The introduction of TNF- alpha -inhibiting biologicals has been a major therapeutic breakthrough in rheumatoid arthritis therapy. Against a background of conventional disease-modifying antirheumatic drug experience, this review focuses on present experiences and possible future developments. TNF inhibition results in profound improvement in the majority of rheumatoid arthritis patients, but non-response and adverse effects need attention. Adalimumab is being filed for approval. Other monoclonal antibodies or receptor constructs are in late development. Small molecule inhibitors of TNF production or signalling are a hot topic. One emerging target is nuclear factor kappa B and selective inhibition has proved effective in animal models of... (More)
The introduction of TNF- alpha -inhibiting biologicals has been a major therapeutic breakthrough in rheumatoid arthritis therapy. Against a background of conventional disease-modifying antirheumatic drug experience, this review focuses on present experiences and possible future developments. TNF inhibition results in profound improvement in the majority of rheumatoid arthritis patients, but non-response and adverse effects need attention. Adalimumab is being filed for approval. Other monoclonal antibodies or receptor constructs are in late development. Small molecule inhibitors of TNF production or signalling are a hot topic. One emerging target is nuclear factor kappa B and selective inhibition has proved effective in animal models of arthritis. Synovial proliferation in rheumatoid arthritis is characterised by diminished apoptosis of fibroblasts, whereas bone marrow precursor cells undergo accelerated apoptosis in active rheumatoid arthritis. Both abnormalities are seemingly ameliorated by TNF inhibition. Anti-apoptotic strategies will soon go into development for control of unresponsive rheumatoid arthritis. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Expert Opinion on Investigational Drugs
volume
11
issue
7
pages
947 - 953
publisher
Ashley Publications
external identifiers
  • wos:000176675900005
  • pmid:12084005
  • scopus:0035986898
ISSN
1744-7658
DOI
10.1517/13543784.11.7.947
language
English
LU publication?
yes
id
cba388f5-e5b3-4e3b-bbd1-89bdb03ca290 (old id 109015)
alternative location
http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12084005&dopt=Abstract
date added to LUP
2007-07-04 14:29:43
date last changed
2017-01-01 04:20:25
@article{cba388f5-e5b3-4e3b-bbd1-89bdb03ca290,
  abstract     = {The introduction of TNF- alpha -inhibiting biologicals has been a major therapeutic breakthrough in rheumatoid arthritis therapy. Against a background of conventional disease-modifying antirheumatic drug experience, this review focuses on present experiences and possible future developments. TNF inhibition results in profound improvement in the majority of rheumatoid arthritis patients, but non-response and adverse effects need attention. Adalimumab is being filed for approval. Other monoclonal antibodies or receptor constructs are in late development. Small molecule inhibitors of TNF production or signalling are a hot topic. One emerging target is nuclear factor kappa B and selective inhibition has proved effective in animal models of arthritis. Synovial proliferation in rheumatoid arthritis is characterised by diminished apoptosis of fibroblasts, whereas bone marrow precursor cells undergo accelerated apoptosis in active rheumatoid arthritis. Both abnormalities are seemingly ameliorated by TNF inhibition. Anti-apoptotic strategies will soon go into development for control of unresponsive rheumatoid arthritis.},
  author       = {Wollheim, Frank},
  issn         = {1744-7658},
  language     = {eng},
  number       = {7},
  pages        = {947--953},
  publisher    = {Ashley Publications},
  series       = {Expert Opinion on Investigational Drugs},
  title        = {TNF inhibition as therapy for rheumatoid arthritis.},
  url          = {http://dx.doi.org/10.1517/13543784.11.7.947},
  volume       = {11},
  year         = {2002},
}